**Name of Journal: *World Journal of Meta-Analysis***

**ESPS Manuscript NO: 27773**

**Manuscript Type:** **Systematic Reviews**

**Statin use and risk of cancer: An overview of meta-analyses**

Undela K *et al*. Statin use and risk of cancer

**Krishna Undela, Chirag SShah, Raj K Mothe**

**Krishna Undela,** Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, SS Nagara, Mysuru 570015, India

**Chirag SShah, Raj K Mothe,** MarksMan Healthcare Solutions, Kopar Khairane, Navi Mumbai 400709, India

**Author contributions:** Undela K designed the study, done literature search, data analysis, manuscript preparation and manuscript editing; Shah CS done literature search, data extraction and manuscript review; Mothe RK done data extraction and manuscript review.

**Conflict-of-interest statement:** Authors declare that they have no conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Krishna Undela, Lecturer,** Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara Nagar, Mysuru 570015, India. [krishnaundela@jssuni.edu.in](mailto:krishnaundela@jssuni.edu.in)

**Telephone:** +91-99-86779870

**Received:** June 15, 2016

**Peer-review started:** June 16, 2016

**First decision:** July 27, 2016

**Revised:** January 14, 2017

**Accepted:** February 18, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To conduct an overview of meta-analyses to critically appraise the evidence and present a comprehensive evaluation of the association between statin use and risk of site specific cancers.

***METHODS***

MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews and Web of Science databases were searched from inception until 31st May 2016. The electronic database search was supplemented by a hand search in PROSPERO and relevant journals which are not indexed in above databases. Meta-analyses that examined the association between statin use and risk of site specific cancers were included. Two reviewers independently screened the literature, abstracted data, and assessed study quality using the Assessment of Multiple Systematic Reviews (AMSTAR) tool.

***RESULTS***

Overall, 38 meta-analyses covered 13 site specific cancers were included. More than half (68%) of the meta-analyses were moderate in quality with an AMSTAR score 4-7 out of a possible 11. Based on current evidence from meta-analyses, use of statin decreases the risk of certain cancers, such as colorectal (8%-12%), gastric (27%-44%), hematological (19%), liver (37%-42%), oesophageal (14%-28%), ovarian (21%) and prostate cancer (7%). On the other side, evidence from meta-analyses also suggests that there is no association between statin use and risk of bladder, breast, endometrial, kidney, lung, pancreatic and skin cancers.

***CONCLUSION***

This overview of meta-analyses with variable quality has been shown that the statins may have a potential role in cancer chemoprevention and reduce the risk of some site specific cancers, but not all.

**Key words:** Statin; Cancer; Meta-analysis

**©The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Statins are one of the most commonly prescribed pharmaceutical agents worldwide and atorvastatin remained the largest source of spending in the class. In recent years, emerging experimental evidence suggests that statins may have a potential role in cancer chemoprevention. However, a large number of randomized controlled trials and observational studies published to examine the association between statin use and risk of site specific cancers were given conflicting results. This overview of meta-analyses with variable quality has been shown that the statins may have a potential role in cancer chemoprevention and reduce the risk of colorectal (8%-12%), gastric (27%-44%), hematological (19%), liver (37%-42%), oesophageal (14%-28%), ovarian (21%) and prostate cancer (7%).

Undela K,Shah CS, Mothe RK. Statin use and risk of cancer: An overview of meta-analyses. *World J Meta-Anal* 2017; In press

**INTRODUCTION**

Statins (HMG-CoA reductase inhibitors) are a class of drugs that reduce serum cholesterol levels by inhibiting HMG-CoA reductase, a rate-limiting enzyme in the mevalonate synthesis pathway[1]. They are commonly used in the management and prevention of cardiovascular diseases. Statins are one of the most commonly prescribed pharmaceutical agents worldwide and atorvastatin remained the largest source of spending in the class[2]. With the effect of recommendations for primary prevention with statins by the recent American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the assessment of cardiovascular risk and on the treatment of blood cholesterol, more than a Billion people are expected take statins[3]. Cancers are among the foremost causes of morbidity and mortality worldwide. There were approximately 14 million new cancer cases and 8.2 million cancer related deaths in 2012. Over the next 2 decades, the number of new cancer cases are expected to rise by about 70%[4].

Apart from reduction in cholesterol level and cardiovascular mortality due to substantially increased use of statins during past three decades[5], there is a long-lasting debate on the potential association between statin use and the risk of cancer. In recent years, emerging experimental evidence suggests that statins may have a potential role in cancer chemoprevention[6-8]. It has been proven that statins activates several mechanisms to cancer cell death. Statins induce cell apoptosis by influencing the expression/activity of proteins involved in cell cycle such as cyclins, cyclin-dependent kinases (CDK), and/or inhibitors of CDK. Statins may inhibit cell cycle progression by both extrinsic and intrinsic pathways. By inhibiting isoprenoid synthesis, statins may lead to changes in molecular pathways dependent on the epidermal growth factor (EGF) receptor. Also, statins may weakens the cell membrane by inhibiting cholesterol synthesis[9]. A large number of randomized controlled trials (RCTs) and observational studies published to examine the association between statin use and risk of site specific cancers were given conflicting results[10]. Many researchers conducted meta-analyses to provide more reliable findings on this association.

In spite of the fact that the meta-analysis show up at the highest level of the evidence in the evidence based practice, comparative data across different domains are often lacking. Overviews are a relatively new approach to generate evidence from several systematic reviews/meta-analyses and become popular in generating the evidence in health care[11].

Therefore, the objective of this overview is to summarize and critically appraise the evidence of relevant meta-analyses to evaluate the association between statin use and risk of site specific cancers.

**MATERIALS AND METHODS**

***Protocol***

A protocol for our overview of meta-analyses were drafted using the Cochrane Handbook for overviews of reviews[10]. The drafted protocol was circulated to subject experts and methodologists for feedback purpose. Based on the feedback, the protocol was revised and final version published in PROSPERO International prospective register of systematic reviews (Registration Number: CRD42014013160) (Supplementary Table).

***Literature search***

A comprehensive literature search was performed in MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews and Web of Science from inception to 31st May 2016 to identify the relevant studies. The search strategy included both medical subject headings (MeSH) and free text terms related to statin and cancer. ‘Hydroxymethylglutaryl-CoA Reductase Inhibitors and Neoplasms’ were the MeSH terms used for statin and cancer, respectively. “Statin(s) or HMG-CoA reductase inhibitor(s) or lipid-lowering agent(s) or atorvastatin or pravastatin or fluvastatin or lovastatin or cerivastatin or mevastatin or rivastatin or rosuvastatin or simvastatin and cancer(s) or neoplasm(s) or malignancy(ies)” were the free text terms used for search strategy. Search strategies were limited to systematic reviews and meta-analyses focused on human participants. In addition, specific journals and cross references of relevant studies were searched manually to capture relevant systematic reviews/meta-analyses and also PROSPERO database was searched to identify completed, unpublished systematic reviews/meta-analyses[12].

***Screening***

Two authors (KU and CSS) were independently involved in title/abstract based and full text based screening to capture all relevant articles using a predefined inclusion and exclusion criteria Disagreements were resolved by discussion and a third author (RKM) was approached whenever required.

***Eligibility criteria***

We included meta-analyses (didn’t find any systematic reviews without meta-analysis) that focused on risk of getting site specific cancers among statin users. Meta-analyses conducted by using RCTs and/or observational studies and published at any point in time were included. Meta-analyses focused on total cancer (*i.e.*, the aggregate of all malignancies) were excluded as all original studies included in these meta-analyses were also included in meta-analyses on site specific cancers with some additional studies. Meta-analyses conducted to identify the effect of statin use on management or prognosis of cancer and also at risk of recurrence of cancer were excluded.

***Data abstraction***

To abstract the relevant data from each included study, specific data abstraction form was drafted, pilot-tested by all authors independently on a random sample of five articles and same were revised after this exercise, as necessary. After finalizing the data abstraction form, two authors (KU and CSS) have analysed all articles independently to capture relevant data. Discrepancies were resolved by discussion and third author (RKM) was approached whenever required. The following information was captured from each study: (1) first author’s last name, year of publication, and country where the study conducted; (2) search methods followed, number of studies identified, type of study designs included, and criteria for study selection and data extraction; (3) methods followed to check the quality of individual studies and to identify the heterogeneity and publication bias; (4) number of subjects and cancer cases involved, outcomes of quality, heterogeneity and publication bias tests, and pooled RR estimates with 95%CIs for primary outcome, secondary outcome and subgroup analyses; and (5) conclusions and if any limitations of the study.

***Quality appraisal***

Risk of bias assessment of included studies was performed by using the Assessment of Multiple Systematic Reviews (AMSTAR) tool[13]. AMSTAR is highly reliable and validated tool assesses the degree to which review methods avoided bias by evaluating the methods against 11 distinct criteria[14]. Quality rating was as follows: A score of 8-11 is high quality; 4-7 is moderate quality and 3 or lower is low quality. Each included meta-analysis was appraised for quality by two authors independently (KU and RKM) and conflicts were resolved by discussion or the involvement of a third author (CSS).

***Data synthesis***

The present work was performed as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Checklist S1).

**RESULTS**

***Search results***

The literature search resulted in 830 titles and abstracts, of which 766 were excluded for not fulfilling the eligibility criteria. Of the 59 full-text articles retrieved and screened in duplicate, 27 were excluded for reasons depicted in Fig. 1. Resulted 32 full-text meta-analyses[15-46] in addition to five relevant conference abstracts[47-51] and one relevant full-text published in World Journal of Meta-analysis[52] were included in this overview. We didn’t find any completed, unpublished systematic reviews/meta-analyses on this topic in PROSPERO.

***Study characteristics***

A total of 38 included meta-analyses covered 13 site specific cancers as an outcome for statin use. Majorly seven meta-analyses published on colorectal cancer[18-20,47-50], followed by gastric (4)[21-24], liver (4)[29-31,52], esophageal (4)[35-37,51], skin (4)[43-46], lung (3)[32-34], prostate (3)[40-42], breast (2)[16,17], hematological (2)[26,27], pancreatic cancers (2)[38,39] and each on bladder[15], gynecological[25] and kidney cancers[28]. The characteristics of the included meta-analyses are presented in Table 1.

All included meta-analyses published between 2005 and 2014; majority [25 (66%)] were published in and after 2012. The first authors of the meta-analyses predominantly based in China (15 studies) followed by Greece (7), United States (7), Canada (2), India (2), United Kingdom (2), and each in Australia, Italy and Japan. Except two studies[42,49] where the information on databases searched not available, remaining 36 (95%) studies searched MEDLINE for relevant studies, followed by EMBASE [22 studies (58%)], Web of Science/Web of Knowledge/Science Citation Index [20 studies (53%)] and Cochrane Library [15 studies (39%)]. Out of 38 included studies, 22 (58%) were included both RCTs and observational studies, nine (24%) studies included only RCTs and five (13%) studies included only observational studies, and information not available for remaining two studies[42,51]. For the assessment of heterogeneity, 34 studies used both Cochrane Q test and I2 test, and information not available for remaining four studies[28,47-49]. Majority (34 (89%)) of the studies assessed publication bias either by using Begg and Mazumdar adjusted rank correlation test and the Egger regression asymmetry test or funnel plot. Two studies[35,36] not assessed publication bias and information not available for remaining two studies[21,29].

***Quality appraisal results***

More than half [26 (68%)] of the meta-analyses were deemed moderate quality with an AMSTAR score 4-7 out of a possible 11. Only six (16%) studies were found to be high quality with score ≥ 8, among these one study was a Cochrane systematic review with the highest quality score 10[43]. One study[21] found to be low quality with the score 0 and five studies[47-51] were not having sufficient information to calculate AMSTAR quality score. Majority of meta-analyses were degraded due to lack of “a priori” design, not searched for gray literature, not provided a list of excluded studies from screening of potentially relevant full-text articles and not used any scale to assess the scientific quality of the included studies in formulating conclusions.

***Outcome results***

The pooled relative risk with 95%CI of the primary outcome of all included studies is shown in forest plot (Figure 2) and it is depicted with sub-group analysis based on cancer type.

**Statin use and risk of bladder cancer:** Only one meta-analysis[15] was conducted to identify the risk of bladder cancer among statin users. There was no association found between statin use and risk of bladder cancer and the result were same even after subgroup analysis by study design and for long-term statin use.

**Statin use and risk of breast cancer:** A meta-analysis published by Bonovas *et al*[16] in 2005 to estimate the association between use of statin and risk of breast cancer by including seven RCTs and nine observational studies. There was no association found between statin use and risk of breast cancer with no heterogeneity among studies. The association becomes same even after subgroup analysis of study design. In 2012, Undela *et al*[17] updated this meta-analysis by including 15 more observational studies published after previous meta-analysis. This study also gives an almost similar conclusion, though there was a heterogeneity identified among studies. Additionally, this updated meta-analysis found 47% reduced risk of recurrence of breast cancer among statin users, but no association between long-term statin use and risk of breast cancer.

**Statin use and risk of colorectal cancer:** Seven meta-analyses (3 full-text[18-20] and 4 conference abstracts[47-50]) published on this association between 2007 and 2014. Almost all the studies included both RCTs and observational studies published between 1995 and 2013 and identified heterogeneity among studies. Except the study by Bardou *et al*[48] (which included only RCTs), remaining all the studies found 8%-12% reduced risk of colorectal cancer among statin users. However, a modest reduction in risk or an effect may be associated with higher doses of statins[18]. Based on the subgroup analyses by two meta-analyses[19,20] published in 2014 (which are full-text and included a maximum number of observational studies), risk reduction was 7%-9% among cohort studies and 8%-16% among case-control studies. Studies included RCTs reported no association between use of statin and risk of colorectal cancer alone for RCTs. One study[50] found there was a 19% reduction in the risk of rectal cancer among statin users. Another study[19] found no association between long-term statin use and risk of colorectal cancer.

**Statin use and risk of gastric cancer:** Four meta-analyses[21-24] published between 2011 and 2014 to identify the risk of gastric cancer among statin users. Except the study conducted by Shimoyama *et al*[21] (published in 2011, searched only PubMed Central and included only RCTs), remaining all studies suggested that the statin use reduces the risk of gastric cancer by 27%-44%, though they identified the heterogeneity among studies. In subgroup analysis, observational studies were found to identify this reduced risk but not RCTs.

**Statin use and risk of gynecological cancer:** A meta-analysis[25] published recently to identify the association between statin use and risk of gynecological cancer. The study included both RCTs and observational studies published between 2000 and 2013 on this association. It didn’t find any association between statin use and risk of gynecological cancer. On subgroup analysis, the association remains same for RCTs and cohort studies, but case-control studies alone show 39% decreased risk of gynecological cancer among statin users. On secondary analysis using available studies, there was no association found between statin use and risk of endometrial cancer, but decreased (21%) risk of ovarian cancer.

**Statin use and risk of hematological cancer:** A meta-analysis published by Bonovas *et al[*26] in 2007 to estimate the association between statin use and risk of hematological cancer by including six RCTs and eight observational studies. No association identified between statin use and risk of hematological cancer. The association found to be same even after subgroup analysis of study design. In 2014, Yi *et al*[27] updated this meta-analysis by including six more observational studies published after Bonovas *et al* meta-analysis and gave contrast results by finding 19% decreased risk of hematological cancer among statin users. On subgroup analysis, this association remains same for observational studies, but not for RCTs.

**Statin use and risk of kidney cancer:** Only one meta-analysis[28] published to estimate the effect of statin use on kidney cancer by including two RCTs and 10 observational studies published between 2001 and 2012. This study found no association between statin use and risk of kidney cancer with heterogeneity among studies. On subgroup and secondary analysis the association remains same among RCTs, cohort and case control studies and also for long-term statin use.

**Statin use and risk of liver cancer:** Four meta-analyses[29-31,52] published in 2013 and 2014 regarding statin use and risk of liver cancer. All studies included observational studies but different in number and only two studies[30,31] included RCTs. All studies found significant heterogeneity among the studies included and shown 37%-42% decreased risk of liver cancer among statin users. This chemoprotective association is more pronounced in the Asian population, where viral hepatitis is the most important risk factor for liver cancer[30]. On subgroup analysis by study design, the risk remains similar (37%-49% decreased risk) among observational studies but not for RCTs.

**Statin use and risk of lung cancer:** Three meta-analyses[32-34] published in 2013 including almost similar number of RCTs and observational studies to identify the association between statin use and risk of lung cancer. All the three found significant heterogeneity among studies and no association between statin use and risk of lung cancer. On subgroup and secondary analysis the association remains same among RCTs, cohort and case control studies and also for long-term statin use.

**Statin use and risk of oesophageal cancer:** Four meta-analyses (3 full-text[35-37] and 1 conference abstract[51]) published in 2012 and 2013 on the association. Only observational studies contributed to the analysis in all studies except the Singh *et al*[37] study also included one RCT (post hoc analysis). Results were consistent among all studies with 14%-28% decreased risk of esophageal cancer among statin users. On subgroup analysis, only case-control studies found with 44% decreased risk of esophageal cancer but not cohort studies and RCT. By using available studies, all the meta-analyses conducted secondary analysis on the risk of Barrett’s esophagus among statin users and found 41%-47% decreased risk. Two studies[37,51] also identified 55% decreased risk of esophageal cancer among long-term statin users.

**Statin use and risk of pancreatic cancer:** A meta-analysis published by Bonovas *et al*[38] in 2008 to estimate the co-relation between statin use and risk of pancreatic cancer by including three RCTs and nine observational studies. There was no relationship between statin use and risk of pancreatic cancer with heterogeneity among studies. The association found to be same even after subgroup analysis of study design. In 2012, Cui *et al*[39] updated this meta-analysis by including four more observational studies published after previous meta-analysis. This study also gives an almost similar conclusion. Additionally, this updated meta-analysis reported no association between long-term statin use and risk of pancreatic cancer.

**Statin use and risk of prostate cancer:** A meta-analysis published by Bonovas *et al*[40] in 2008 to estimate the association between statin use and risk of prostate cancer by including six RCTs and 13 observational studies. No association identified between statin use and risk of prostate cancer. The association remains same even after subgroup analysis of study design and also for long-term statin use. In 2012, Bansal *et al*[41] updated this meta-analysis by including 14 more observational studies published after Bonovas *et al* meta-analysis and gave contrast results by finding small (7%) but significant decreased risk of prostate cancer among statin users. But in a subgroup analysis of study design, no association observed between cohort and case-control studies alone. Both the studies also tried to identify the risk of advanced prostate cancer among statin users and found 23%-30% decreased risk. On the other hand, a study conducted by Zhang *et al*[42] in 2013 by including only seven studies published after Bonovas *et al*[40] meta-analysis and found a 19% increased risk of prostate cancer among statin users.

**Statin use and risk of skin cancer (melanoma):** Four meta-analyses[43-46] conducted on this association, including one Cochrane systematic review published in 2005. All studies included only RCTs except the study by Li *et al*[46] also included 11 observational studies. All the studies found no association between statin use and risk of melanoma and also the association found to be same for non-melanoma skin cancer by Li *et al*[46] study. Interestingly, one RCT[43,44] suggested that the lovastatin can decrease the risk of melanoma by 48%.

**DISCUSSION**

Meta-analytic evidence of association between statin use and risk of site specific cancers was piling since last decade. This overview of 38 meta-analyses covered 13 site specific cancers revealed that the statin use may reduce the risk of certain types of cancers like colorectal (8%-12%), gastric (27%-44%), hematological (19%), liver (37%-42%), esophageal (14%-28%), ovarian (21%) and prostate cancer (7%). On the other hand, some evidence also suggests that there is no association between statin use and risk of bladder, breast, endometrial, kidney, lung, pancreatic and skin cancers. On secondary analysis, few meta-analyses suggested that statin use can also reduce the risk of rectal cancer (19%), advanced prostate cancer (23-30%), Barret’s esophagus (47%) and also reduce the risk of recurrence of breast cancer (47%).

In this review, we tried to identify the change in the risk of cancer among different types, doses and duration of statin use with the available information. Some of the meta-analyses categorized statins according to whether they were lipophilic (simvastatin, lovastatin, fluvastatin, and atorvastin) or hydrophilic (pravastatin and rosuvastatin) and conducted subgroup analysis. The studies didn’t find any statistically significant association between lipophilic or hydrophilic statins and risk of colorectal cancer[18,20], haematological cancer[26], lung cancer[33], pancreatic cancer[38,39] and skin cancer[45]. In contrast, one meta-analysis showed an association between lipophilic statin use and colorectal cancer risk (RR = 0.88, 95%CI: 0.85–0.93) and a null association between hydrophilic statin use and colorectal cancer risk (RR = 0.88, 95%CI: 0.76–1.02)[19]; and another meta-analysis found a significant decrease in liver cancer risk for both lipophilic statin (RR = 0.57, 95%CI: 0.50-0.65) and hydrophilic statins (RR = 0.59, 95%CI: 0.41-0.84). The same study also revealed that higher cumulative dose of statin use, defined as statin use over 180 cumulative defined daily doses (cDDDs) or 0.5 years (cumulative duration), showed a trend towards more risk reduction of liver cancer (RR = 0.53, 95%CI: 0.36-0.79)[31]. Some of the studies also conducted secondary analysis to identify the association between long-term statin use (usually ≥ 5 years) and risk of cancer, and identified reduced risk of oesophageal cancer (55%)[37,51], ovarian cancer (52%)[25], but not for bladder [15], breast[17], colorectal[19], endometrial[25], kidney[28], Lung[33], pancreatic[39] and prostate cancers[40,41].

Recently published overview to identify the role of statin use in cancer prevention and modifying cancer-related outcomes also come out with similar conclusions[53]. However, this study suffers with some limitations in methodology and not covered few cancer types. Moreover, a recent meta-analysis of long-term efficacy and safety of statin treatment confirmed that statin treatment did not increase the incidence of cancer and deaths from cancers[54]. Despite the examinations on statins consequences for tumor cells have proceeded from the mid 1990s, the exact mechanism that could clarify the anticancer effect of statins still unclear. Different types, dose and route of administration of statins being used, type/stage of tumors and time of exposure to statins may impact the mechanisms that lead to cell-cycle arrest and induction of apoptosis. One review observed that statins may decrease the cholesterol levels, leads to further changes in cell flagging[9].

According to recent laboratory studies, statins seems to have chemo-preventive affect against cancer at various sites. Evidence suggests that statins are selectively localized to the liver, and only < 5% dose reaches the systemic circulation. This low systemic availability uncertians chemo-protective nature of statin[15,16].

We have made efforts to minimize the risk of bias in every step of this overview. However, this overview has few limitations. First, glitches in the nature of the primary data included in 38 meta-analyses; RCTs have not been adequately powered to detect potentially small differences in cancer risk due to the small number of cancer cases as it was not the primary outcome of these trials and the observational data may have suffered some common limitations of pharmacoepidemiological studies. Secondly, as most of the findings come from observational studies, there may be a chance of presenting “healthy-user bias” for part of the beneficial effects of statins.

Statins are a promising group of drugs in cancer treatment because of their ability to reduce both cholesterol and isoprenoid levels. Meta-analyses of variable quality showed that the statins may have a potential role in cancer chemoprevention and reduce the risk of certain site specific cancers, but not all. Until a definitive benefit is demonstrated by randomized controlled trials, statins cannot be recommended either for cancer prevention or for modifying cancer-related outcomes.

**COMMENTS**

***Background***

In recent years, emerging experimental evidence suggests that statins may have a potential role in cancer chemoprevention. However, a large number of randomized controlled trials (RCTs) and observational studies published to examine the association between statin use and risk of site specific cancers were given conflicting results.

***Research frontiers***

The objective of this overview is to summarize and critically appraise the evidence of relevant meta-analyses and present a comprehensive evaluation of the association between statin use and risk of site specific cancers.

***Innovations and breakthroughs***

This overview of 38 meta-analyses covered 13 site specific cancers revealed that the statin use may reduce the risk of certain types of cancers like colorectal (8%-12%), gastric (27%-44%), hematological (19%), liver (37%-42%), esophageal (14%-28%), ovarian (21%) and prostate cancer (7%). On the other hand, some evidence also suggests that there is no association between statin use and risk of bladder, breast, endometrial, kidney, lung, pancreatic and skin cancers. On secondary analysis, few meta-analyses suggested that statin use can also reduce the risk of rectal cancer (19%), advanced prostate cancer (23%-30%), Barret’s esophagus (47%) and also reduce the risk of recurrence of breast cancer (47%).

***Applications***

Statins are a promising group of drugs in cancer treatment because of their ability to reduce both cholesterol and isoprenoid levels. Meta-analyses of variable quality showed that the statins may have a potential role in cancer chemoprevention and reduce the risk of certain site specific cancers, but not all. Until a definitive benefit is demonstrated by randomized controlled trials, statins cannot be recommended either for cancer prevention or for modifying cancer-related outcomes.

***Peer-review***

These authors made a comprehensive review of meta-analyses on statin use and risk of cancer. They also made tables and figures, which make readers easy to catch the study methods, strength and results from each meta-analysis. It will be informative for readers interested in this topic.

**REFERENCES**

1 **Goldstein JL**, Brown MS. Regulation of the mevalonate pathway. *Nature* 1990; **343**: 425-430 [PMID: 1967820 DOI: 10.1038/343425a0]

2 IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2011. [accessed 2015 May 15]. Available from: URL: http: //www.imshealth.com/.../IHII\_Medicines\_in\_U.S\_Report\_2011.pdf

3 **Ioannidis JP**. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. *JAMA* 2014; **311**: 463-464 [PMID: 24296612 DOI: 10.1001/jama.2013.284657]

4 World Health Organization. Cancer. [accessed 2015 May 15]. Available from: URL: http: //www.who.int/mediacentre/factsheets/fs297/en

5 **Wijeysundera HC**, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella R, O'Flaherty M, Krahn M, Capewell S. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. *JAMA* 2010; **303**: 1841-1847 [PMID: 20460623 DOI: 10.1001/jama.2010.580]

6 **Demierre MF**, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. *Nat Rev Cancer* 2005; **5**: 930-942 [PMID: 16341084 DOI: 10.1038/nrc1751]

7 **Gazzerro P**, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M. Pharmacological actions of statins: a critical appraisal in the management of cancer. *Pharmacol Rev* 2012; **64**: 102-146 [PMID: 22106090 DOI: 10.1124/pr.111.004994]

8 **Katz MS**. Therapy insight: Potential of statins for cancer chemoprevention and therapy. *Nat Clin Pract Oncol* 2005; **2**: 82-89 [PMID: 16264880 DOI: 10.1038/ncponc0097]

9 **Matusewicz L**, Meissner J, Toporkiewicz M, Sikorski AF. The effect of statins on cancer cells--review. *Tumour Biol* 2015; **36**: 4889-4904 [PMID: 26002574 DOI: 10.1007/s13277-015-3551-7]

10 **Higgins JPT,** Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. [accessed 2015 May 16]. www.cochrane-handbook.org

11 **Hartling L**, Chisholm A, Thomson D, Dryden DM. A descriptive analysis of overviews of reviews published between 2000 and 2011. *PLoS One* 2012; **7**: e49667 [PMID: 23166744 DOI: 10.1371/journal.pone.0049667]

12 **National Institute for Health Research (NIH).** PROSPERO database. [accessed 2015 Apr 15]. Available from: URL: http: //www.crd.york.ac.uk/Prospero

13 **Shea BJ**, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol* 2009; **62**: 1013-1020 [PMID: 19230606 DOI: 10.1016/j.jclinepi.2008.10.009]

14 **Shea BJ**, Bouter LM, Peterson J, Boers M, Andersson N, Ortiz Z, Ramsay T, Bai A, Shukla VK, Grimshaw JM. External validation of a measurement tool to assess systematic reviews (AMSTAR). *PLoS One* 2007; **2**: e1350 [PMID: 18159233 DOI: 10.1371/journal.pone.0001350]

15 **Zhang XL**, Geng J, Zhang XP, Peng B, Che JP, Yan Y, Wang GC, Xia SQ, Wu Y, Zheng JH. Statin use and risk of bladder cancer: a meta-analysis. *Cancer Causes Control* 2013; **24**: 769-776 [PMID: 23361339 DOI: 10.1007/s10552-013-0159-3]

16 **Bonovas S**, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. *J Clin Oncol* 2005; **23**: 8606-8612 [PMID: 16260694 DOI: 10.1200/JCO.2005.02.7045]

17 **Undela K**, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. *Breast Cancer Res Treat* 2012; **135**: 261-269 [PMID: 22806241 DOI: 10.1007/s10549-012-2154-x]

18 **Bonovas S**, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. *J Clin Oncol* 2007; **25**: 3462-3468 [PMID: 17687150 DOI: 10.1200/JCO.2007.10.8936]

19 **Liu Y**, Tang W, Wang J, Xie L, Li T, He Y, Deng Y, Peng Q, Li S, Qin X. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. *Cancer Causes Control* 2014; **25**: 237-249 [PMID: 24265089 DOI: 10.1007/s10552-013-0326-6]

20 **Lytras T**, Nikolopoulos G, Bonovas S. Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. *World J Gastroenterol* 2014; **20**: 1858-1870 [PMID: 24587664 DOI: 10.3748/wjg.v20.i7.1858]

21 **Shimoyama S**. Statins and gastric cancer risk. *Hepatogastroenterology* 2011; **58**: 1057-1061 [PMID: 21830442]

22 **Singh PP**, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. *Ann Oncol* 2013; **24**: 1721-1730 [PMID: 23599253 DOI: 10.1093/annonc/mdt150]

23 **Wu XD**, Zeng K, Xue FQ, Chen JH, Chen YQ. Statins are associated with reduced risk of gastric cancer: a meta-analysis. *Eur J Clin Pharmacol* 2013; **69**: 1855-1860 [PMID: 23748751 DOI: 10.1007/s00228-013-1547-z]

24 **Ma Z**, Wang W, Jin G, Chu P, Li H. Effect of statins on gastric cancer incidence: a meta-analysis of case control studies. *J Cancer Res Ther* 2014; **10**: 859-865 [PMID: 25579519 DOI: 10.4103/0973-1482.138218]

25 **Liu Y**, Qin A, Li T, Qin X, Li S. Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials. *Gynecol Oncol* 2014; **133**: 647-655 [PMID: 24736024 DOI: 10.1016/j.ygyno.2014.04.007]

26 **Bonovas S**, Filioussi K, Tsantes A, Sitaras NM. Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. *Br J Clin Pharmacol* 2007; **64**: 255-262 [PMID: 17578480 DOI: 10.1111/j.1365-2125.2007.02959.x]

27 **Yi X**, Jia W, Jin Y, Zhen S. Statin use is associated with reduced risk of haematological malignancies: evidence from a meta-analysis. *PLoS One* 2014; **9**: e87019 [PMID: 24498014 DOI: PMC3909054]

28 **Zhang XL**, Liu M, Qian J, Zheng JH, Zhang XP, Guo CC, Geng J, Peng B, Che JP, Wu Y. Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. *Br J Clin Pharmacol* 2014; **77**: 458-465 [PMID: 23879311 DOI: 10.1111/bcp.12210]

29 **Pradelli D**, Soranna D, Scotti L, Zambon A, Catapano A, Mancia G, La Vecchia C, Corrao G. Statins and primary liver cancer: a meta-analysis of observational studies. *Eur J Cancer Prev* 2013; **22**: 229-234 [PMID: 23010949 DOI: 10.1097/CEJ.0b013e328358761a]

30 **Singh S**, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. *Gastroenterology* 2013; **144**: 323-332 [PMID: 23063971 DOI: 10.1053/j.gastro.2012.10.005]

31 **Shi M**, Zheng H, Nie B, Gong W, Cui X. Statin use and risk of liver cancer: an update meta-analysis. *BMJ Open* 2014; **4**: e005399 [PMID: 25227628 DOI: 10.1136/bmjopen-2014-005399]

32 **Deng Z**, Zhang S, Yi L, Chen S. Can statins reduce risk of lung cancer, especially among elderly people? A meta-analysis. *Chin J Cancer Res* 2013; **25**: 679-688 [PMID: 24385695 DOI: 10.3978/j.issn.1000-9604.2013.11.02]

33 **Tan M**, Song X, Zhang G, Peng A, Li X, Li M, Liu Y, Wang C. Statins and the risk of lung cancer: a meta-analysis. *PLoS One* 2013; **8**: e57349 [PMID: 23468972 DOI: 10.1371/journal.pone.0057349]

34 **Wang J**, Li C, Tao H, Cheng Y, Han L, Li X, Hu Y. Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials. *PLoS One* 2013; **8**: e77950 [PMID: 24205041 DOI: 10.1371/journal.pone.0077950]

35 **Alexandre L**, Clark AB, Cheong E, Lewis MP, Hart AR. Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. *Aliment Pharmacol Ther* 2012; **36**: 301-311 [PMID: 22716127 DOI: 10.1111/j.1365-2036.2012.05194.x]

36 **Beales IL**, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. *World J Gastrointest Pharmacol Ther* 2013; **4**: 69-79 [PMID: 23919219 DOI: 10.4292/wjgpt.v4.i3.69]

37 **Singh S**, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 620-629 [PMID: 23357487 DOI: 10.1016/j.cgh.2012.12.036]

38 **Bonovas S**, Filioussi K, Sitaras NM. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. *Am J Gastroenterol* 2008; **103**: 2646-2651 [PMID: 18684187 DOI: 10.1111/j.1572-0241.2008.02051.x]

39 **Cui X**, Xie Y, Chen M, Li J, Liao X, Shen J, Shi M, Li W, Zheng H, Jiang B. Statin use and risk of pancreatic cancer: a meta-analysis. *Cancer Causes Control* 2012; **23**: 1099-1111 [PMID: 22562222 DOI: 10.1007/s10552-012-9979-9]

40 **Bonovas S**, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. *Int J Cancer* 2008; **123**: 899-904 [PMID: 18491405 DOI: 10.1002/ijc.23550]

41 **Bansal D**, Undela K, D'Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. *PLoS One* 2012; **7**: e46691 [PMID: 23049713 DOI: 10.1371/journal.pone.0046691]

42 **Zhang Y**, Zang T. Association between statin usage and prostate cancer prevention: a refined meta-analysis based on literature from the years 2005-2010. *Urol Int* 2013; **90**: 259-262 [PMID: 23052323 DOI: 10.1159/000341977]

43 **Dellavalle RP**, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, McNealy K, Schilling L. Statins and fibrates for preventing melanoma. *Cochrane Database Syst Rev* 2005: CD003697 [PMID: 16235336 DOI: 10.1002/14651858.CD003697.pub2]

44 **Freeman SR**, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, Dellavalle RP. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. *J Natl Cancer Inst* 2006; **98**: 1538-1546 [PMID: 17077356 DOI: 10.1093/jnci/djj412]

45 **Bonovas S**, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, Sitaras NM. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. *Eur J Epidemiol* 2010; **25**: 29-35 [PMID: 19844794 DOI: 10.1007/s10654-009-9396-x]

46 **Li X**, Wu XB, Chen Q. Statin use is not associated with reduced risk of skin cancer: a meta-analysis. *Br J Cancer* 2014; **110**: 802-807 [PMID: 24366301 DOI: 10.1038/bjc.2013.762]

47 **Bardoua MBA,** Martel M. Prolonged statin use weakly decreases the risk of colorectal cancer (CRC): a meta-analysis of 21 observational studies totaling more than 1.6 million patients. Socie´te´ Franc¸aise de Pharmacologie et de The´rapeutique. 2010; **24** (Suppl 1): 69

48 **Bardoua MBA,** Martel M. Statin use does not appear to confer a significant protection against the risk of colorectal cancer (CRC): a meta-analysis of eleven randomized clinical trials (RCT). Socie´te´ Franc¸aise de Pharmacologie et de The´rapeutique. 2010; **24** (Suppl 1): 64

49 **Ditah IJS,** Kutait A, Tageja N, Msallaty Z, Kingah P, Antaki F. Statin Use and the Risk of Colorectal Cancer: Has Recent Evidence Shift ed Our Opinion? A Meta-analysis Involving More Than 1.7 Million Participants. *Am J Gastroenterol* 2010; **105** (Suppl 1): S141

50 **Samadder NJGA,** Rennert G, Gruber SB. Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 22 Observational Studies. *Gastroenterol* 2010; **138** (Suppl 1): S477

51 **Andrici JTM,** Eslick GD. Statin Use Reduces the Risk of Esophageal Cancer: A Meta-Analysis. *Gastroenterol* 2013; **144** (Suppl 1): S675

52 **Zhang HGC,** Fang L, Yao S. Statin use and risk of liver cancer: A meta-analysis of 7 studies involving more than 4.7 million patients. *World J Meta-Anal* 2013; **1:** 130-7

53 **Bonovas S**. Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes? *Drugs* 2014; **74**: 1841-1848 [PMID: 25288321 DOI: 10.1007/s40265-014-0309-2]

54 **Lv HL**, Jin DM, Liu M, Liu YM, Wang JF, Geng DF. Long-term efficacy and safety of statin treatment beyond six years: a meta-analysis of randomized controlled trials with extended follow-up. *Pharmacol Res* 2014; **81**: 64-73 [PMID: 24602799 DOI: 10.1016/j.phrs.2014.02.006]

**P-Reviewer:** Kim HS, Su CC **S-Editor:** Song XX **L-Editor:** **E-Editor:**

**Table 1 Characteristics of the included meta-analyses**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First author, Yeara (Country)b** | **Databases searched (Period)c** | **Studies included (n)** | **Studies published between (Years)** | **Total subjects involved** | **Total cancer cases** | **Heterogeneity presents?** | **Pooled RR (95%CI) for primary outcome (n)d** | **Pooled RR (95%CI) for secondary outcome (n)** | **Pooled RR (95%CI) for Sub-group analysise** | **AMSTAR score** |
| **Bladder cancer** | | | | | | | | | | |
| Zhang X, 2013 (China) [15] | MEDLINE, EMBASE and Ovid (January 1966 to October 2012) | RCTs (3), Cohort (5) and CC (5) | 2001-2012 | 1266268 | 2511 | Yes (*q* = 0.001, *I2*= 62.6 %) | 1.07 (0.95-1.21) (↔) | LSU = 1.21 (0.92-1.51) (8) (↔) | RCTs = 0.83 (0.63-1.10) (↔);  Cohort = 1.11 (0.91-1.35) (↔);  CC = 1.12 (0.98-1.28) (↔) | 7 |
| **Breast cancer** | | | | | | | | | | |
| Bonovas S, 2005 (Greece) [16] | MEDLINE (1966 to March2005) and SCI (1970 to March2005) | RCTs (7), Cohort (4) and CC (5) | 1993-2005 | 327238 | 24599 | No (*q* = 0.12, *I2*= 30%) | 1.03 (0.93-1.14) (↔) | None | RCTs = 1.04 (0.81-1.33) (↔) ;  Cohort = 1.06 (0.92-1.21) (↔); CC = 0.99 (0.83-1.18) (↔) | 7 |
| Undela K, 2012 (India) [17] | PubMed (1966 to January 2012) and ASCO, AACR conference abstracts | Cohort (13) and CC (11) | 1993-2011 | 2440988 | 76759 | Yes (*q* < 0.001, *I2* = 57%) | 0.99 (0.94-1.04) (↔) | LSU = 1.03 (0.96-1.11) (10) (↔); Recurrence 0.53 (0.37-0.76) (2) (↓) | Cohort = 1.01 (0.98-1.04) (↔); CC = 0.95 (0.84-1.08) (↔) | 5 |
| **Colorectal cancer** | | | | | | | | | | |
| Bonovas S, 2007 (Greece) [18] | MEDLINE (1966 to December 2006) and WS (1970 to December 2006) | RCTs (6), Cohort (3) and CC (9) | 2000-2007 | 1527721 | 38734 | No (*q* = 0.35, *I2*= 7%) | 0.92 (0.90-0.95) (↓) | None | RCTs = 0.95 (0.81-1.11) (↔);  Cohort = 0.96 (0.84-1.11) (↔); CC = 0.92 (0.89-0.95) (↓) | 7 |
| Bardou M, 2010 (Canada)f [47] | EMBASE, MEDLINE, CENTRAL,  and ISI WK | RCTs (11) | NA | 95984 | 1659 | No (NA) | 0.94 (0.85-1.04) (↔) | None | NA | -- |
| Bardou M, 2010 (Canada)f [48] | EMBASE, MEDLINE, CENTRAL,  and ISI WK | Cohort (8) and CC (13) | NA | 1606234 | NA | No (NA) | 0.92 (0.87-0.98) (↓) | None | Cohort = 0.89 (0.75-1.05) (↔); CC = 0.92 (0.90-0.94) (↓) | -- |
| Ditah I, 2010 (United States)f [49] | NA | RCTs (6), Cohort (6) and CC (12) | Up to Jun. 2010 | >1.7 million | NA | NA | 0.89 (0.85-0.94) (↓) | None | RCTs = 0.95 (0.80-1.13) (↔); Cohort = 0.89 (0.85-0.94) (↓); CC = 0.86 (0.79-0.94) (↓) | -- |
| Samadder NJ, 2010 (United States)f [50] | MEDLINE, EMBASE, WS and abstracts of national GI conferences (up to October  2009) | Cohort (5) and CC (17) | NA | 2.5 million | NA | Yes (*q* < 0.01, *I2* = 47%) | 0.88 (0.84-0.93) (↓) | Rectal = 0.81 (0.62-1.05) (8) (↓) | Cohort = 0.88 (0.84-0.93) (↓); CC = 0.90 (0.86-0.94) (↓) | -- |
| Liu Y, 2014 (China) [19] | PubMed, EMBASE, WS, Cochrane Library (up to 30th July 2013) | RCTs (11), Cohort (13) and CC (18) | 1995-2013 | 7908674 | 519317 | Yes (*q* < 0.001, *I2* = 66.5%) | 0.90 (0.86-0.95) (↓) | LSU = 0.96 (0.88–1.04) (20) (↔) | RCTs = 0.96, (0.85–1.08) (↔); Cohort = 0.93 (0.87–0.99) (↓); CC = 0.84 (0.76–0.93) (↓) | 7 |
| Lytras T, 2014 (Greece) [20] | MEDLINE (1966 to July 2013) | RCTs (8), Cohort (13) and CC (19) | 1996-2013 | 8224019 | 130992 | Yes (q < 0.001, *I2* = 71%) | 0.91 (0.87-0.96) (↓) | None | RCTs = 0.90 (0.78-1.04) (↔); Cohort = 0.91 (0.83-1.00) (↓); CC = 0.92 (0.87-0.98) (↓) | 0034 |
| **Gastric cancer** | | | | | | | | | | |
| Shimoyama S, 2011 (Japan) [21] | PubMed Central (1993 to 2008) | RCTs (6) | 1994-2007 | 37851 | 284 | No (*q* = 0.42, *I2* = 0.0%) | 1.37 (0.57-3.25) (3) (↔) | UGIC = 1.20 (0.94-1.53) (3) (↔) | None | 0 |
| Singh PP, 2013 (United States) [22] | PubMed (1966 to 1st December 2012), EMBASE (1988 to 1st December 2012) and WS (1993 to 1st December 2012) | RCTs (*post-hoc* analyses) (3), Cohort (1) and CC (7) | 2004-2012 | 5459975 | 5581 | Yes (*q* < 0.01, *I2* = 89%) | 0.68 (0.51–0.91) (↓) | None | RCTs = 0.83 (0.66–1.05) (↔); OSs = 0.65 (0.45–0.93) (↓) | 8 |
| Wu X, 2013 (China) [23] | PubMed and EMBASE (up to March 2013) | RCTs (3), Cohort (3) and CC (5) | 2004-2013 | 1136918 | 7611 | Yes (*q* < 0.001, *I2* = 88.9%) | 0.73 (0.58-0.93) (↓) | None | RCTs = 0.84 (0.61-1.14) (↔); Cohort = 0.87 (0.77-0.99) (↓); CC = 0.56 (0.31-1.01) (↔) | 6 |
| Ma Z, 2014 (China) [24] | Cochrane CRCT (Issue 12, 2012), PubMed, EMBASE,  ISI WK, CNKI, CBML,  CSJFD and  Wanfang Database | CC (6) | 2004-2013 | 60793 | 5993 | Yes (*q* < 0.001, *I2* = 97%) | 0.56 (0.35-0.90) (↓) | None | None | 6 |
| **Gynaecologic cancer** | | | | | | | | | | |
| Liu Y, 2014 (China) [25] | PubMed, EMBASE and Cochrane Library (up to 10th February 2014) | RCTs (4), Cohort (5) and CC (5) | 2000-2013 | 928721 | 12904 | Yes (*q* = 0.016, *I2* = 42.3%) | 0.89 (0.78-1.01) (↔) | Endometrial = 0.90 (0.75-1.07) (10) (↔); Ovarian = 0.79 (0.64-0.98) (5) (↓) | RCTs = 0.97 (0.62-1.50) (↔); Cohort = 0.97 (0.87-1.09) (↔); CC = 0.61 (0.40-0.91) (↓) | 7 |
| **Haematological cancer** | | | | | | | | | | |
| Bonovas S, 2007 (Greece) [26] | MEDLINE (1966 to December 2006) and WS (1970 to December 2006) | RCTs (6), Cohort (1) and CC (7) | 1996-2006 | 412053 | 5619 | Yes (*q* < 0.001, *I2* = 71%) | 0.85 (0.64-1.12) (↔) | None | RCTs = 0.92 (0.72-1.16) (↔); OSs = 0.83 (0.53-1.29) (↔) | 5 |
| Yi X, 2014 (China) [27] | PubMed, EMBASE and Cochrane CRCT (January 1966 to July 2013) | RCTs (6), Cohort (4), CC (10) | 1996-2012 | 1139584 | 15297 | Yes (*q* < 0.001, *I2* = 59%) | 0.81 (0.70-0.92) (↓) | None | RCTs = 0.92 (0.77-1.09) (↔); OSs = 0.79 (0.67-0.93) (↓) | 4 |
| **Kidney cancer** | | | | | | | | | | |
| Zhang X, 2014 (China) [28] | MEDLINE, EMBASE and Cochrane Library (January 1966 to October 2012) | RCTs (2), Cohort (5) and CC (5) | 2001- 2012 | 3143236 | 2829 | Yes (*q* < 0.001, *I2* = 87.8%) | 0.92 (0.71- 1.19) (↔) | LSU = 1.01 (0.83-1.22) (6) (↔) | RCTs = 1.01 (0.57-1.79) (↔); Cohort = 1.07 (0.96-1.20) (↔); CC = 0.74 (0.45-1.23) (↔) | 5 |
| **Liver cancer** | | | | | | | | | | |
| Pradelli D, 2013 (Italy) [29] | MEDLINE (up to March 2012) | Cohort (3) and CC (2) | NA | NA | 2574 | Yes (*q* < 0.001, *I2* = 65%) | 0.58 (0.46-0.74) (↓) | LSU = 0.66 (0.55-0.80) (↓) | None | 6 |
| Singh S, 2013 (United States) [30] | MEDLINE (1966 to 25th May 2012), EMBASE (1988 to 25th May 2012) and WS (1993 to 25th May 2012) | RCTs (3), Cohort (4) and CC (3) | 2005-2012 | 1459417 | 4298 | Yes (*q* = 0.08, *I2* = 58%) | 0.63 (0.52–0.76) (↓) | None | RCTs = 0.95 (0.62-1.45) (↔); OSs = 0.60 (0.49-0.73) (↓) | 8 |
| Zhang H, 2013 (China) [52] | MEDLINE, EMBASE and Cochrane Library (January 1966 to March2013) | Cohort (4) and CC (3) | 2005-2013 | 4725593 | 9785 | Yes (*q* = 0.004, *I2* = 68.6%) | 0.61 (0.49-0.76) (↓) | None | Cohort = 0.62 (0.3-0.89) (↓); CC = 0.63 (0.49-0.82) (↓) | 5 |
| Shi M, 2014 (China) [31] | PubMed, BIOSIS Previews, WS, EMBASE, EBSCO and Cochrane Library (from inception to 5th March 2014) | RCT (IPD analysis) (1), Cohort (5) and CC (6) | 2005-2013 | 5640313 | 35756 | Yes (*q* < 0.001, *I2* = 65%) | 0.58 (0.51-0.67) (↓) | HCDS = 0.53 (0.36-0.79) (6) (↓) | RCT = 1.06 (0.66-1.71) (↔); Cohort = 0.51 (0.44-0.58) (↓); CC = 0.63 (0.54-0.73) (↓) | 6 |
| **Lung cancer** | | | | | | | | | | |
| Deng Z, 2013 (China)g [32] | MEDLINE, EMBASE and WS (from inception to September 2013) | RCTs (8)  Cohort (7) and CC (8) | 1998-2012 | 2795302 | 38024 | OSs = Yes (*q* < 0.001, *I2* = 94.9%)  RCTs = No (*q* = 0.483, *I2* = 0.0%) | 1.03 (0.96-1.11) (↔) | None | RCTs = 0.95 (0.85-1.06) (↔); Cohort = 0.94 (0.82-1.07) (↔); CC = 0.85 (0.62-1.16) (↔) | 6 |
| Tan M, 2013 (China) [33] | PubMed (up to March 2012) | RCTs (5), Cohort (7) and CC (7) | 1998-2011 | 5009404 | 38013 | Yes (*q* < 0.001, *I2* = 93.3%) | 0.89 (0.77–1.03) (↔) | LSU = 0.81 (0.42-1.56) (↔) | RCTs = 0.91 (0.76-1.09) (↔); Cohort = 0.94 (0.82-1.07) (↔); CC = 0.82 (0.57-1.16) (↔) | 6 |
| Wang J, 2013 (China) [34] | MEDLINE, EMBASE and Cochrane Library (January 1966 to November 2012) | RCTs (5), Cohort (8) and CC (7) | 1998-2012 | 4980009 | 37560 | Yes (*q* < 0.001, *I2* = 93.6%) | 0.89 (0.78-1.02) (↔) | LSU = 0.80 (0.39-1.64) (6) (↔) | RCTs = 0.92 (0.79-1.06) (↔); Cohort = 0.93 (0.82-1.06) (↔); CC = 0.81 (0.57-1.16) (↔) | 8 |
| **Oesophageal cancer** | | | | | | | | | | |
| Alexandre L, 2012 (United Kingdom) [35] | PubMed, EMBASE and Cochrane CRCT (up to December 2011) | Cohort (3) | 2004-2011 | 35214 | 9310 | No (*q* = 0.88, *I2* = 0.0%) | 0.86 (0.78-0.94) (↓) | In patients with BE = 0.53 (0.36-0.78) (↓) | None | 7 |
| Andrici J, 2013 (Australia)f [51] | MEDLINE, PubMed, EMBASE and Current Contents  Connect (up to 29th October 2012) | 7 studies | NA | NA | NA | No (*q* = 0.31, *I2* = 15%) | 0.75 (0.67-0.84) (↓) | In patients with BE = 0.56 (0.41-0.76) (↓);  LSU = 0.45 (0.31-0.67) (↓) | Prospective = 0.75 (0.67-0.86) (↓); Retrospective = 0.68 (0.54-0.86) (↓) | -- |
| Beales ILP, 2013 (United Kingdom) [36] | The PubMed, EMBASE, Cochrane Library, WS, Wiley Interscience and Google Scholar (up to 1st February 2013) | Cohort (5) and CC (6) | 2004-2012 | 6454353 | 371203 | No (*q* = 0.42, *I2* = 0.0%) | 0.81 (0.75-0.88) (6) (↓) | In patients with BE = 0.56 (0.41-0.76) (4) (↓) | None | 6 |
| Singh S, 2013 (United States) [37] | MEDLINE (1980 to 31st Aug. 2012), EMBASE (1988 to 31st Aug. 2012) and WS (1993 to 31st August 2012) | RCT (*Post hoc* analyses) (1), Cohort (5) and CC (7) | 2004-2012 | 1132969 | 9285 | Yes (*q* < 0.01, *I2* = 74%) | 0.72 (0.60-0.86) (↓) | In patients with BE = 0.59 (0.45-0.78) (5) (↓); LSU = 0.44 (0.24-0.78) (2) (↓) | RCT = 0.98 (0.69-1.40) (↔); Cohort = 0.79 (0.62-1.02) (↔); CC = 0.66 (0.51-0.85) (↓) | 8 |
| **Pancreatic cancer** | | | | | | | | | | |
| Bonovas S, 2008 (Greece) [38] | MEDLINE, Scopus, Google Scholar, and SCI (up to December 2007) and AACO and AACR conference abstracts | RCTs (3), Cohort (4) and CC (5) | 1993-2007 | 914601 | 3521 | Yes (*q* < 0.001, *I2*= 86%) | 0.88 (0.63-1.23) (↔) | None | RCTs = 0.99 (0.44-2.21) (↔); Cohort = 1.11 (0.95-1.29) (↔); CC = 0.70 (0.37-1.33) (↔) | 7 |
| Cui X, 2012 (China) [39] | MEDLINE, BIOSIS Previews and Cochrane Library (from inception to 30th August 2011) | RCTs (3), Cohort (5) and CC (8) | 2001-2011 | 1692863 | 7807 | Yes (*q* < 0.001, *I2* = 81%) | 0.89 (0.74-1.07) (↔) | LSU = 0.97 (0.76-1.23) (5) (↔) | RCTs = 0.99 (0.44-2.21) (↔); Cohort = 1.05 (0.93-1.19) (↔); CC = 0.74 (0.51-1.07) (↔) | 8 |
| **Prostate cancer** | | | | | | | | | | |
| Bonovas S, 2008 (Greece) [40] | MEDLINE (1966 to November 2007) and WK-SCI Expanded (1970 to November 2007) | RCTs (6), Cohort (6) and CC (7) | 1993-2007 | > 884871 | 62372 | Yes (*q* < 0.001, *I2* = 98%) | 0.95 (0.73-1.23) (↔) | LSU = 0.93 (0.77-1.13) (6) (↔); APC = 0.77 (0.64-0.93) (5) (↓) | RCTs = 1.06 (0.93-1.20) (↔); Cohort = 0.98 (0.89-1.09) (↔); CC = 0.74 (0.46-1.20) (↔) | 5 |
| Bansal D, 2012 (India) [41] | PubMed (up to February 2012) | Cohort (15) and Case-control (12) | 1993-2011 | 1893571 | 56847 | Yes (*q* < 0.001, *I2* = 82%) | 0.93 (0.87-0.99) (↓) | LSU = 0.94 (0.84-1.05) (11) (↔); APC = 0.80 (0.70-0.90) (7) (↓) | Cohort = 0.93 (0.87-1.01) (↔); CC = 0.87 (0.72-1.05) (↔) | 7 |
| Zhang Y, 2013 (China) [42] | NA | 7 studies | 2005-2010 | NA | NA | NA | 1.19 (1.01-1.40) (↑) | NA | NA | 6 |
| **Skin cancer (Melanoma)** | | | | | | | | | | |
| Dellavalle R, 2005 (United States)[43] | Cochrane Skin Group Specialised Register (up to February 2003) and CENTRAL (Issue 1, 2005),  MEDLINE (up to March 2003), EMBASE (up to September 2003), CANCERLIT (up to October 2002), WS (up to May 2003) | RCTs (7) | 1993-1998 | 31198 | 126 | No (*q* = 0.23, *I2* = 29%) | 0.90 (0.56-1.44) (↔) | Lovastatin = 0.52 (0.27-0.99) (1) (↓) | None | 10 |
| Freeman SR, 2006 (United States) [44] | MEDLINE (from January 1966 to March 2003), EMBASE  (from January 1980 to September 2003), The Cochrane  CRCT (up to March2003),  CANCERLIT (from January 1975 to October 2002), and  WS — SCI (from January 1970  to May 2003) | RCTs (12) | 1993-2003 | 39426 | 127 | No (*q* = 0.31, *I2* = 16.6%) | 0.87 (0.61-1.23) (↔) | Lovastatin = 0.52 (0.27-0.99) (1) (↓) | None | 6 |
| Bonovas S, 2010 (Greece) [45] | MEDLINE, Scopus, Google Scholar and  SCI Expanded (up to June 2009) | RCTs (16) | 1994-2006 | 62568 | 165 | No (*q* = 0.25, *I2* = 22%) | 0.92 (0.67-1.26) (↔) | None | None | 6 |
| Li X, 2014 (China) [46] | PubMed ( up to 2013) and WS (1985–2013) | RCTs (17), Cohort (4) and CC (7) | 1995-2013 | 517887 | 11787 | Yes (*q* < 0.07, *I2* = 33.8%) | 0.94 (0.85-1.04) (24) (↔); NMSC = 1.03 (0.90-1.19) (14) (↔) | None | None | 4 |

aPublication year; bCountry of study conducted; cPeriod of literature search; dn mentioned only where the number of studies differ from studies included; eThough many subgroup analyses conducted in individual studies, here we focused mainly on subgroup analysis based on study design due to space constraint; fConference abstracts; gConducted among elderly people. APC: Advanced prostate cancer; BE: Barrett’s oesophagus; CBML: China BioMedical Literature; CC: Case-control; CNKI: Chinese National Knowledge Infrastructure; CRCT: Central Register of Controlled Trials; CSJFD: Chinese Scientific Journal Full‑text Database; GI: Gastro-intestinal; HCDS: Higher cumulative dosage of statin; *I2*: *I2* test value; IPD: Individual patient data; ISI WK: Institute for Scientific Information Web of knowledge (Former term for Web of science); LSU: Long-term statin use; n: Number of studies; NA: Not available; NMSC: Non-melanoma skin cancer; Oss: Observational studies; *q*: Cochran Q test *P* value; RCTs: Randomized controlled trials; RR: Relative risk; SCI: Science citation index; UGIC: Upper gastrointestinal cancer; WS: Web of science; ↔: Non-significant association; ↓: Statistically significantly decreased risk; ↑: Statistically significantly increased risk.

N=830 citations from MEDLINE, EMBASE, Cochrane Library and Web of Science

N=766 excluded titles and abstracts:

1. Not a systematic review/meta-analysis (n=379)
2. Outcome is not a cancer (n=182)
3. Treatment is not statin use (n=109)
4. Duplicate studies (n=96)

N=59 potentially relevant full-text articles

N=5 potentially relevant conference abstracts

N=1 potentially relevant full-text article from World Journal of Meta-analysis (added)

N=27 excluded full-text articles:

1. Meta-analysis on total cancer (not on site specific cancer) (n=22)
2. Meta-analysis on recurrence of cancer (n=3)
3. Meta-analysis on management or prognosis of cancer (n=2)

N=38 included meta-analyses

(N=33 full-text articles and N=5 conference abstracts)

n=1 on bladder cancer

n=2 on breast cancer

n=7 on colorectal cancer

n=4 on gastric cancer

n=1 on gynaecological cancer

n=2 on haematological cancer

n=1 on kidney cancer

n=4 on liver cancer

n=3 on lung cancer


n=4 on oesophageal cancer

n=2 on pancreatic cancer

n=3 on prostate cancer

n=4 on skin cancer (melanoma)

**Figure 1.Study flow.**

****

**Figure 2 Forest plot of pooled relative risk with 95%CI of primary outcome from all included studies.**